Navigation Links
PNAS Publishes Preclinical Results of EntreMed's 2ME2 for Multiple Sclerosis
Date:12/4/2012

tiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer.  Its second compound, 2ME2, has been investigated in clinical trials in oncology patients, and is the subject of a successful IND filing for clinical use to treat RA.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

Forward Looking Statements           

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under development; results in precli
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
2. Express Scripts Publishes Inaugural Drug Trend Quarterly, Provides First Comprehensive Overview of U.S. Prescription Drug Spending for 2012
3. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
4. Varian Medical Systems Publishes 2012 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
5. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
6. American Journal of Obstetrics and Gynecology Publishes PeriGen Research on Shoulder Dystocia
7. Pharmspective Publishes New Assessment of Impact of State Exchanges on Key Insurers and Pharma
8. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
9. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
10. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... NEW YORK, Oct. 6, 2011 Avista Capital Partners, ... has hired Hakan Bjorklund, the departing Chief Executive Officer ... closely with Avista on the development of Nycomed during ... to Takeda Pharmaceuticals Company Limited for Euro 9.6 billion. ...
... Scios Inc. announced an agreement with the United States Department ... a prescription medication for patients with heart failure. ... guilty plea to a single misdemeanor violation of the Food, ... million fine. Scios acknowledges that NATRECOR® was misbranded ...
Cached Medicine Technology:Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive 2Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive 3
(Date:4/22/2014)... The latest scientific advances and emerging therapies in heart ... main annual meeting of the Heart Failure Association (HFA) ... also hear breaking news on acute heart failure during ... is part of the main congress. , The event ... the Megaron Athens International Conference Centre (MAICC). The full ...
(Date:4/22/2014)... 10 Americans support mandated coverage of birth control medications, ... the University of Michigan Health System. , Women, blacks, ... at home, and adults with private or public insurance ... universal coverage of birth control medications, according to the ... American Medical Association ( JAMA ). , Individuals ...
(Date:4/22/2014)... In parallel with modern man ( Homo sapiens ), there ... lived side by side, such as Neanderthals and the recently ... survived. What was it in our genetic makeup that ... is known about our unique genetic makeup as distinguished from ... that we are the only species among them ,to survive. ...
(Date:4/22/2014)... serious health conditions may be influenced by low exposure ... A study has revealed how men,s testosterone levels may ... some men have less of the hormone than others ... Low levels of the hormone have been linked ... shown that the cells responsible for producing testosterone in ...
(Date:4/22/2014)... more likely to have a child who develops an ... recent study from researchers from the Drexel University School ... Sweden provides more insight into how the risk associated ... and found that the risk of having a child ... older parents., In the study, published in the February ...
Breaking Medicine News(10 mins):Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:What gave us the advantage over extinct types of humans? 2Health News:Child's autism risk accelerates with mother's age over 30 2Health News:Child's autism risk accelerates with mother's age over 30 3
... Lab Internacional,S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or ... March 31, 2009. All figures included herein,were prepared ... nominal,Mexican pesos. Also, the following consolidated figures show the ... , , 1Q09 Highlights (vs. 1Q08), ...
... April 28 Claimsnet.com inc. (OTC ... solutions for the healthcare industry, today reported its results ... March 31, 2009.For the quarter ended March 31, 2009, ... from the $490,000 reported for the first quarter of ...
... The American Physical Society commends President Obama,s commitment to ... implementing policies that will enhance science and math ... 3 percent of the nation,s gross domestic product to ... ensure that the U.S. develops effective solutions to challenges ...
... battle swine flu epidemicWASHINGTON, April 28 Transportation Security Officers ... precautionary measures as they screen passengers who may have been ... Employees said today.In an urgent letter to TSA Acting Administrator ... , That a respirator, ...
... The President of the American Academy of Disaster Medicine,s ... and analysis from a disaster medicine perspective on the ... explanation of why improvements are needed to the U.S. ... any virus or pathogen; how disaster medicine specialists are ...
... CLEVELAND, April 28 DATATRAK International, Inc. (Nasdaq: ... on global eClinical solutions for the clinical trials industry, ... CRO, has become the newest member of the DATATRAK ... growing list of CROs, CPI is able to expand ...
Cached Medicine News:Health News:Genomma Lab Internacional Announces First Quarter 2009 Results 2Health News:Genomma Lab Internacional Announces First Quarter 2009 Results 3Health News:Claimsnet.com Reports First Quarter 2009 Results 2Health News:Claimsnet.com Reports First Quarter 2009 Results 3Health News:APS commends President Obama's commitment to greater investment in science 2Health News:AFGE: TSA Must Do More to Protect Its Workforce and the Public 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 4Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 2Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 3Health News:German CRO clinicalprojects international GmbH Becomes Newest Member of DATATRAK's CRO Connect Program(TM) 4
... The CELL-DYN 1800 is the latest ... technology used since the founding of the ... QC and data management capabilities, the CELL-DYN ... labs. The CELL-DYN 1800 is smaller than ...
... Precision Net Point-of-Care Data Networking ... the power of data networking. In ... results can be transferred from nursing ... laboratory. Data is instantly available to ...
... EarlyDetect® Menopause Test is a one ... menopause has occured. This test can ... follicle-stimulating hormone (FSH), which indicates whether ... simple to use and in a ...
... Teco Diagnostics manufactures fine urine chemistry ... urine chemistry reagent strips from start ... offer more economical prices compared to ... quality. Teco Diagnostics urine reagent strips ...
Medicine Products: